Method for diagnosing cholangiocarcinoma via bacterial metagenomic analysis

Abstract

The present invention relates to a method of diagnosing cholangiocarcinoma through bacterial metagenomic analysis, and more particularly to a method of diagnosing cholangiocarcinoma by analyzing an increase or decrease in content of specific bacteria-derived extracellular vesicles through bacterial metagenomic analysis using subject-derived samples. Extracellular vesicles secreted from bacteria present in the environment are absorbed into the body, and can directly affect the occurrence of cancer, and cholangiocarcinoma is difficult to diagnose early before symptoms appear so that effective treatment is difficult. Therefore, by previous diagnosis of the risk for the onset of cholangiocarcinoma through metagenomic analysis of bacterial extracellular vesicles using human-derived samples according to the present invention, the risk group of cholangiocarcinoma can be diagnosed and predicted early to delay or prevent the onset of cholangiocarcinoma through proper management, and early diagnosis can be performed even after the onset, thereby reducing the incidence of cholangiocarcinoma and increasing the therapeutic effect. In addition, the progression of cancer can be improved or the recurrence of cancer may be prevented by avoiding the exposure of causative factors through metagenomic analysis for patients diagnosed with cholangiocarcinoma.